Journal of Clinical Oncology · 2012 · 294 citations · 122 references
MedicineOncologyChemotherapyGenitourinary OncologyNeoplasiaCancer RiskGerm Cell TumorsGermline Cancer SusceptibilityMalignant NeoplasmsTesticular CancerGerm Cell Tumor ChemotherapyMale Germ Cell ToxicityPsychosocial Late EffectsPulmonary Late EffectsRenal Adverse EffectsTesticular Cancer ChemotherapyTesticular Cancer DiagnosisTesticular Cancer Incidence
Germ cell testicular cancer (TC) represents a malignancy with high cure rates. Since the introduction of cisplatin-based chemotherapy in the late 1970s, the 5-year survival rate has increased considerably, and it is currently above 95%. Because TC is usually diagnosed before the age of 40 years, these men can expect to live for another 40 to 50 years after being successfully treated. This success, however, is hampered by an increased risk of long-term and late effects of treatment. Secondary malignant neoplasms and cardiovascular disease represent the most common potentially life-threatening late effects, typically occurring more than 10 years after treatment. Other long-term effects include pulmonary toxicity, nephrotoxicity, neurotoxicity, decreased fertility, hypogonadism, and psychosocial problems. The incidence and time to onset of these various adverse effects vary according to treatment type and intensity. There is still little knowledge about underlying mechanisms and genetic susceptibility of the various adverse effects. Apart from treatment burden, it is not yet possible to identify patients who are at high risk for certain late effects after TC treatment. In this clinical review, we present the current status regarding different somatic and psychosocial long-term late effects after treatment for TC, based on Medline searches and our own research. Moreover, we postulate recommendations for general medical evaluations that should begin after treatment is completed and continue during follow-up.
122
The metabolic syndrome—a new worldwide definition
K. G. M. M. Alberti, Paul Zimmet, Jonathan E. Shaw · The Lancet · 2005 · 9.3K citations
Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data
Arduino Verdecchia, Silvia Francisci, Hermann Brenner et al. · The Lancet Oncology · 2007 · 1.3K citations
Medicine, Biostatistics, Oncology +17